
-
Verona Pharma ADR NasdaqGM:VRNA Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Location: 3 More London Riverside, London, SE1 2RE, United Kingdom | Website: https://www.veronapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
56.34B
Cash
401.4M
Avg Qtr Burn
-30.04M
Short % of Float
1.48%
Insider Ownership
11.95%
Institutional Own.
90.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ohtuvayre (Ensifentrine-nebulized) Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
Ensifentrine (Nebulized) Details Cystic fibrosis | Phase 2 Update | |
Ensifentrine (Nebulized) Details Lung disease, Asthma | Phase 2 Update | |
Ensifentrine (Inhaled) Details COVID-19 | Failed Discontinued |